Physician profile
Yusef Williams
NPI 1699904243
$3,566.52
in general payments reported to CMS, 2019-2025
32 companies · $445 in 2025
The $445 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $131 · 2020: $295 · 2021: $795 · 2022: $645 · 2023: $564 · 2024: $691 · 2025: $445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,699.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $896.50 | 2021-2025 | Qulipta, Vraylar |
| Novo Nordisk INC | $334.53 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $306.85 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Merck Sharp & Dohme LLC | $248.54 | 2020-2023 | Verquvo, Belsomra |
| Lilly USA, LLC | $229.69 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Esperion Therapeutics, INC. | $186.79 | 2021-2022 | |
| Pfizer INC. | $172.21 | 2019-2025 | |
| Abbott Laboratories | $145.69 | 2021 | |
| Nevro Corp. | $120.65 | 2022-2024 | Senza |
| Biohaven Pharmaceuticals, INC. | $114.85 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $97.87 | 2022-2025 | |
| Eisai INC. | $87.93 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $72.68 | 2022-2024 | |
| Glaxosmithkline, LLC. | $68.81 | 2023-2024 | Trelegy Ellipta |
| Exact Sciences Corporation | $63.39 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $60.22 | 2022 | |
| Janssen Pharmaceuticals, INC | $48.60 | 2019-2020 | |
| Boston Scientific Corporation | $38.15 | 2020 | |
| Sanofi-Aventis U.S. LLC | $32.28 | 2020 | |
| Dexcom, INC. | $28.32 | 2021-2023 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $25.86 | 2025 | Caplyta |
| Xeris Pharmaceuticals, INC. | $24.24 | 2025 | Gvoke Hypopen |
| Shire North American Group INC | $23.62 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.63 | 2022 | |
| Amarin Pharma, INC. | $18.08 | 2021 | |
| Horizon Therapeutics Plc | $17.69 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.95 | 2025 | Zoryve |
| Idorsia Pharmaceuticals US INC | $14.51 | 2022 | |
| Axsome Therapeutics, INC. | $14.44 | 2025 | Auvelity |
| Amgen INC. | $14.28 | 2023 | Prolia, Evenity |
| Teva Pharmaceuticals USA, INC. | $12.18 | 2019 | |
| Genentech USA, INC. | $11.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yusef Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.